Company Overview
Company Type: Private Company
Website: www.allucent.com
Global Number of Employees (Latest): 250
Year Founded: 1988
Total Amount Raised ($ mm)†: -
Total Rounds of Funding**:1
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Allucent, a contract research and development organization, provides strategic and tactical support for pharmaceutical, biotechnology, and medical device industries in North America and internationally. The company offers services ranging from the design and management of preclinical and clinical studies to the submission of regulatory documents required for marketing approval. It also provides clinical trial, regulatory, medical and pharmacovigilance, nonclinical safety, data management and biostatistics, medical writing, quality assurance, project management, and investigator registry services, and chemistry, manufacturing, and control services. Allucent was formerly known as Cato Research Ltd. and changed its name to Allucent in May 2022. The company was founded in 1988 and is headquartered in Cary, North Carolina. It has locations in San Francisco and San Diego, California, Boston, Massachusetts, Washington, District of Columbia, Montreal, Canada, Frankfurt and Cologne, Germany, Graz, Austria, Tel Aviv, Israel, Hyderabad, India, Johannesburg, South Africa, and Riga.


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
2000 Centregreen Way Suite 300 | Cary, NC | 27513 | United States
Phone: 919-361-2286   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
JLL Partners, LLC
Nov-09-2018
Minority
-
Growth
-
Water Street Healthcare Partners, LLC
Nov-09-2018
Minority
-
Growth
Michael Brennan

Investment Arms
Cato BioVentures


Financial Information (Currency: Reported Currency, in mm)
Total Revenue
 35.5
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 250
Net Debt
-
U.S. Number of Employees 2018
 113
U.S. Number of Employees 2017
 107
U.S. Last Year Employee Growth %
 5.6
* Hover over data point numbers for date and source.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.

Key Professionals
Name
Title
Goldberg, Mark A.
Executive Chairman & CEO
Sutton, Lynda 
Co-Founder, President and Chief Regulatory Officer
Cato, Allen Easley
Co-Founder & Director
Pharand, Daniel 
Chief Financial Officer
Daniels, Linda Markus
Chief Legal Officer and Vice President of Corporate Development
Bell, Bill W.
Vice President of Marketing and Business Development
Whelan, Trisha L.
Senior Director of Human Resources
Cato, Allen 
COO of CRSD, San Francisco, Canada & South Africa & MD of CRSD, San Francisco, Canada & South Africa
DeVos, Leslie 
President of Consulting Business
Furci, Patrizia G.
Managing Director and Vice President of Clinical Research - Cato Research Canada
Millham, Robert D.
President of Clinical Trial Operations
Moore, Katy 
President of Growing Clinical Pharmacology, Modeling & Simulation Division

Key Board Members
Name
Title
Goldberg, Mark A.
Executive Chairman & CEO
Cato, Allen Easley
Co-Founder & Director


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Pharm-Olam International (UK) Limited
Pharm-Olam International (UK) Limited offers clinical research services. The company was founded in 1994 and is based in Bracknell, United Kingdom. As of May 3, 2022, Pharm-Olam International (UK) Limited operates as a subsidiary of Allucent.

Europe
Life Sciences Tools and Services
47.00
-
-
Nuventra, Inc.
Nuventra, Inc. provides customers clinical pharmacology services. The company offers pharmacokinetics and pharmacodynamics services, toxicokinetic solutions, population pharmacokinetics, modeling and simulation, regulatory affair services, study design and conduct, scientific writing, data management, and strategic advice services. Nuventra, Inc. was formerly known as ClinPharm Consulting, LLC and changed its name to Nuventra, Inc. in January 2013. Nuventra, Inc. was founded in 2008 and is based in Durham, North Carolina. As of May 26, 2021, Nuventra, Inc. operates as a subsidiary of Cato Research Ltd.

United States and Canada
Life Sciences Tools and Services
9.00
-
-
Array Biostatistics LLC
Array Biostatistics LLC operates as a full-service biostatistical and statistical programming CRO for the biopharmaceutical industry. It tracks records of successful drug and device development in phase I-IV clinical trials, patient registries, and regulatory submissions including integrated summaries of safety and effectiveness. The company was founded in 2012 and is based in Wilmington, North Carolina. As of September 15, 2020, Array Biostatistics LLC operates as a subsidiary of Cato Research Ltd.

United States and Canada
Life Sciences Tools and Services
-
-
-
Specialized Medical Services-oncology BV
Specialized Medical Services-oncology BV, a contract research organization, provides clinical trial services ranging from start-up to completion and Phase I to IV. The company was founded in 2007 and is based in Schiphol, the Netherlands. As of October 28, 2019, Specialized Medical Services-oncology BV operates as a subsidiary of Cato Research Ltd.

Europe
Life Sciences Tools and Services
0.00
-
-
Studika Monitoring + Audit GmbH
As of February 20, 2003, Studika Monitoring + Audit GmbH is a subsidiary of Cato Research Ltd.

Europe
Life Sciences Tools and Services
-
-
-


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Goldberg, Mark A.
Executive Chairman & CEO
919-361-2286
-

Sutton, Lynda 
Co-Founder, President and Chief Regulatory Officer
919-361-2286
-

Cato, Allen Easley
Co-Founder & Director
919-361-2286
-

Pharand, Daniel 
Chief Financial Officer
919-361-2286
-
dpharand@pharcan.com
Daniels, Linda Markus
Chief Legal Officer and Vice President of Corporate Development
919-361-2286
-

Bell, Bill W.
Vice President of Marketing and Business Development
919-361-2286
-

Whelan, Trisha L.
Senior Director of Human Resources
919-361-2286
-

Cato, Allen 
COO of CRSD, San Francisco, Canada & South Africa & MD of CRSD, San Francisco, Canada & South Africa
919-361-2286
-

DeVos, Leslie 
President of Consulting Business
919-361-2286
-

Furci, Patrizia G.
Managing Director and Vice President of Clinical Research - Cato Research Canada
919-361-2286
-

Millham, Robert D.
President of Clinical Trial Operations
919-361-2286
-

Moore, Katy 
President of Growing Clinical Pharmacology, Modeling & Simulation Division
919-361-2286
-

* denotes that the relationship is proprietary

Key Board Members Details
Name
Title
Phone
Fax
Email
Goldberg, Mark A.
Executive Chairman & CEO
919-361-2286
-

Cato, Allen Easley
Co-Founder & Director
919-361-2286
-

* denotes that the relationship is proprietary


News Headlines
No News is currently available for the selected sources.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-05-2022
May-03-2022
Merger/Acquisition
Buyer
Pharm-Olam International (UK) Limited
Cato Research Ltd. (nka:Allucent)

-
May-26-2021
May-26-2021
Merger/Acquisition
Buyer
Nuventra, Inc.
Cato Research Ltd. (nka:Allucent)

-
Sep-15-2020
Sep-15-2020
Merger/Acquisition
Buyer
Array Biostatistics LLC
Cato Research Ltd. (nka:Allucent)

8.00
Oct-28-2019
Oct-28-2019
Merger/Acquisition
Buyer
Specialized Medical Services-oncology BV
Cato Research Ltd. (nka:Allucent)

-
Nov-09-2018
Nov-09-2018
Private Placement
Target
Cato Research Ltd. (nka:Allucent)
JLL Partners, LLC,Water Street Healthcare Partners, LLC

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Aug-28-2023
Client Announcements
Allucent Wins BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
May-24-2023
Company Conference Presentations
Allucent Presents at World Orphan Drug Congress USA, May-24-2023 12:10 PM
May-23-2023
Product-Related Announcements
Allucent Launches Decentralized Clinical Trial Solution At 2023 World Orphan Drug Congress
Jan-09-2023
Company Conference Presentations
Allucent Presents at BIO Partnering at JPM 2023, Jan-09-2023
Nov-14-2022
Company Conference Presentations
Allucent Presents at World Orphan Drug Congress Europe, Nov-14-2022


Company Coverage
This company is not on any Coverage List.


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.



Debt Summary*
*No applicable Debt Capital Structure Data is available for this company.
Maturity Schedule
There is no data available for this company

Financial Analysis
No notes exist.


Recommendations
No notes exist.


SWOT Analysis
Strengths:
Weaknesses:
No notes exist.
No notes exist.
Opportunities:
Threats:
No notes exist.
No notes exist.

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
